0001104659-23-080008.txt : 20230711
0001104659-23-080008.hdr.sgml : 20230711
20230711164641
ACCESSION NUMBER: 0001104659-23-080008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230710
FILED AS OF DATE: 20230711
DATE AS OF CHANGE: 20230711
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fahey Sandell Jacquelyn
CENTRAL INDEX KEY: 0001984647
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37625
FILM NUMBER: 231082567
MAIL ADDRESS:
STREET 1: C/O VOYAGER THERAPEUTICS, INC.
STREET 2: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Voyager Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640266
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-5340
MAIL ADDRESS:
STREET 1: 64 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
tm2320946-3_4seq1.xml
OWNERSHIP DOCUMENT
X0407
4
2023-07-10
0
0001640266
Voyager Therapeutics, Inc.
VYGR
0001984647
Fahey Sandell Jacquelyn
C/O VOYAGER THERAPEUTICS, INC.,
64 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Legal Officer
0
Stock Option (Right to Buy)
10.18
2023-07-10
4
A
0
122000
0
A
2033-07-10
Common Stock
122000
122000
D
This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).
The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.
/s/ Jacquelyn Fahey Sandell
2023-07-11